Abbott Laboratories (NYSE:ABT)

biotech

Top Health Care Earnings for the Week Ahead

Earnings season is hitting its stride next week, and we have taken a look at companies in a variety of sectors that will be posting results next week. The health ...
Read Full Story »
generic drugs

Can Perrigo Get More From Mylan?

Just before lunchtime on Wednesday, generic drug maker Mylan N.V. (NASDAQ: MYL) proposed to acquire rival Perrigo Co. PLC (NYSE: PRGO) for $205 per share in cash and stock. Perrigo, ...
Read Full Story »
generic drugs

Does the Mylan Secondary Make Its Stock Cheap?

Mylan N.V. (NASDAQ: MYL) announced that it would have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the offering would be valued at $2.08 billion. Total assets owned by ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Cameron, Dollar General, Genworth, Groupon, SunPower, Visa, Yahoo and More

Stocks were hit hard early Friday before the preliminary fourth-quarter gross domestic product reading. What has been observed over and over is that investors have bought the dips and pullbacks ...
Read Full Story »
135093244

Companies That Benefit as Sexually Transmitted Disease Cases Keep Growing

Although it is a subject many investors would like to avoid, for obvious reasons, the growth in the number of sexually transmitted diseases (or STDs, as they are called) is ...
Read Full Story »
investing

Jefferies Has 5 Stocks to Buy With Big Catalysts This Week

With earnings season in full force this week, the presentation of quarterly numbers will likely drive the direction of many stocks. Despite a huge turnaround by the markets on Friday, ...
Read Full Story »
Tax

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late. The move is also ...
Read Full Story »
Abbott Laboratories Logo

Abbott, Mylan Join Forces to Dodge U.S. Taxes

Add one more to the litany of pharmaceutical company mergers that are being made to avoid U.S. taxes. Abbott Laboratories (NYSE: ABT) has agreed to sell its non-U.S. generic drug business ...
Read Full Story »
Pentagon

Pentagon Awards $10.5 Billion in Defense Contracts

The U.S. Department of Defense awarded 19 defense contracts in its Tuesday evening announcement of contract awards. The total value of contracts awarded was $10.46 billion. Among the defense contractors ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Altria, CenturyLink, Micron, GoGo, AT&T and More

Stocks are indicated marginally lower on Monday, but the Dow Jones Industrial Average and S&P 500 hit new all-time highs early last week. Investors want to make profits in good ...
Read Full Story »
Target logo

Why Target Shares Fell Rather Than Rose on CEO Firing

Shares of Target Corp. (NYSE: TGT) are taking a hit of around 3% Monday morning following the resignation/firing of Chairman/President/CEO Gregg Steinhafel. The now-former CEO is being replaced temporarily by ...
Read Full Story »
145922793

Five Top Health Care Names From RBC to Buy Now

The intense analysis of quantitative managers may seem like drudgery, but it can turn up absolute gems for investors looking for solid long ideas. In fact, firms like RBC use ...
Read Full Story »
Merger

Baxter Split-Up, a Page From Abbott’s Playbook

Baxter International Inc. (NYSE: BAX) is taking an activist investor role of its own. The health care company has announced that it is splitting itself into two separate companies, in ...
Read Full Story »
Wall St Bull statue

Jefferies Highest Conviction Franchise Picks for Big Upside in 2014

During the end of last year and into 2014, most of the firms we cover on Wall Street had their top stock pick lists for the coming year. Most companies ...
Read Full Story »
Wall St Bull statue

Top Analyst Upgrades and Stocks to Buy: AIG, Genworth, SolarCity and More

Stocks are effectively at all-time highs, and this is the first full week of trading for 2014. Wall Street firms are making their annual outlook reports and calling on the ...
Read Full Story »